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I.   INTRODUCTION 
Under U.S. law, parents are granted broad power and control over their 
children’s bodies. In the healthcare setting, the law vests parents with decision-
making authority for most medical decisions.1 This general rule applies when minors 
seek to undergo body modification through cosmetic surgery, such as breast 
implants.2 Thus, a consenting parent who finds a willing provider to perform breast 
implant surgery on a minor can authorize this invasive, but elective, surgery on the 
child’s behalf.  
                                                          
 1 Parham v. J.R., 442 U.S. 584, 603 (1979) (noting that “parents can and must make” 
medical decisions regarding their teenage children); see generally Lawrence Schlam & Joseph 
P. Wood, Informed Consent to the Medical Treatment of Minors: Law and Practice, 10 
HEALTH MATRIX 141, 148–52 (2000) (explaining that doctors must obtain parental consent 
prior to performing most medical procedures on minors). 
 2 Diana Zuckerman & Anisha Abraham, Teenagers and Cosmetic Surgery: Focus on 
Breast Implant and Liposuction, 43 J. ADOLESCENT HEALTH 318, 322 (2008) (stating that an 
adolescent under eighteen can undergo cosmetic surgery, including breast implants, as long as 
there is parental consent). 
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Omnipresent media reports and other cultural portrayals of cosmetic surgery 
performed on youth indicate that the parental authority to consent to breast implant 
surgery on behalf of minors is real and exercised, rather than simply theoretical. One 
news report, for example, profiled several teenaged girls who received breast 
implants.3 These teens were sometimes offered breast implants as gifts from parents 
to celebrate a momentous birthday or a graduation.4 Others indicated that their 
parents had consented to the procedure to help the teen remedy issues with low self-
esteem, or to improve her overall happiness.5  
Regardless of what motivates parents to consent to breast implant surgery for 
their children, the available data show that parents are doing so in growing numbers. 
For example, between 2010 and 2011 the number of breast implant surgeries 
performed on young women ranging from ages thirteen to nineteen increased four 
percent.6 In a nation where hundreds of thousands of breast implant surgeries are 
performed each year across the general population,7 year-to-year increases of this 
magnitude can equal thousands of additional surgeries performed each year.  
In many situations it is perfectly reasonable, and in fact preferable, to allow 
parents to consent to medical interventions on the behalf of their minor children. 
Parents enjoy a constitutional liberty interest in directing the upbringing of their 
children; it is presumed that parents will act in the best interests of their children 
when they substitute their experiences and judgment for a child’s in making 
important life decisions.8 This article highlights, however, that when it comes to 
providing consent for their children to undergo medically unnecessary breast implant 
surgery, the rationales underlying the presumption of deference to parents and 
medical providers fail. Because there are reasons to believe this traditional consent 
framework will not protect the best interests of minors who seek breast implants, this 
article argues that it is appropriate for the federal government to mandate a national 
minimum age of eighteen for receiving breast implants. 
This article begins in Part II by providing a brief background on breast implant 
surgery and its prevalence amongst minors. Part III outlines representative situations 
in which the federal government sets a national minimum age for access to products 
or procedures that can be unsafe for minors. Part IV illustrates scenarios where 
national age minimums are not deemed appropriate. Part V explores the rationales 
underlying both the use and rejection of age restrictions; it explains why a national 
minimum age for breast implants would serve similar policy goals as other age-
based access controls. Part VI specifically addresses two primary counterarguments: 
highlighting why it is appropriate to impinge on both the physician-patient 
                                                          
 3 John Stossel, Why Are Parents Buying Their Girls the Gift of Surgery?, ABC NEWS 
(July 16, 2007), http://abcnews.go.com/2020/story?id=875821#.ULk6oYXLQ7A. 
 4 Id.  
 5 Id. 
 6 AM. SOC’Y OF PLASTIC SURGEONS, American Society of Plastic Surgeons 2011 Plastic 
Surgery Statistics Report 14 (2012), http://www.plasticsurgery.org/Documents/news-
resources/statistics/2011-statistics/2011_Stats_Full_Report.pdf [hereinafter ASPS 2011 
Statistics Report]. 
 7 Id. at 8. 
 8 See infra text accompanying notes 181–190. 




relationship and parental autonomy in the context of breast implants for minors. 
Finally, Part VII concludes the article.  
 
II.   BACKGROUND ON BREAST IMPLANT SURGERY AND ITS PREVALENCE AMONGST 
MINORS 
A. The Basics of Breast Implant Surgery 
Plastic surgery procedures are typically segmented into two subgroups: 
reconstructive and corrective.9 Reconstructive surgery is designed to “correct a clear 
abnormality.”10 For example, the correction of a cleft lip or palate is considered 
reconstructive surgery. On the other hand, corrective or cosmetic surgery is “defined 
as surgery to improve a ‘normal’ appearance.”11 Corrective and cosmetic surgeries 
are performed solely for aesthetic reasons and include procedures such as rhinoplasty 
(colloquially called a “nose job”) and breast implant surgery.12  
Breast implants are medical devices implanted underneath breast tissue or the 
chest muscle. Cosmetically, breast implants are used to increase breast size. Two 
types of breast implants are approved for sale by the Food and Drug Administration 
(FDA) in the United States: saline-filled and silicone gel-filled.13 The FDA has 
formally approved saline-filled breast implants for women eighteen and older, and 
silicone gel-filled implants for women twenty-two and older.14 Notably, however, it 
is legal for doctors to perform breast implant surgery using either type of implant in 
minors under eighteen as an “off-label” use with parental consent.15  
Breast implant surgery is typically performed on an outpatient basis and requires 
general anesthesia.16 During the procedure, the breast implant device is placed inside 
a pocket created under the breast tissue or in the pectoralis major muscle of the 
patient.17 Immediately following the breast implant surgery, patients typically 
experience postoperative discomfort for several days, must wear a surgical bra for 
                                                          
 9 Kuni Simis et al., After Plastic Surgery: Adolescent-Reported Appearance Ratings and 
Appearance-Related Burdens in Patient and General Population Groups, 109 PLASTIC & 
RECONSTRUCTIVE SURGERY 9, 9–10 (2002); see also Derrick Diaz, Minors and Cosmetic 
Surgery: An Argument for State Intervention, 14 DEPAUL J. HEALTH CARE L. 235, 238 (2012). 
 10 Zuckerman & Abraham, supra note 2, at 318. 
 11 Id. 
 12 Id. 
 13 Medical Devices: Breast Implants, FDA, http://www.fda.gov/medicaldevices/ 
Productsandmedicalprocedures/implantsandprosthetics/breastimplants/default.htm (last 
updated Sept. 17, 2013). 
 14 Zuckerman & Abraham, supra note 2, at 319. 
 15 Id. Off-label use of this kind is permissible pursuant to the FDA’s policy of approving 
medical products only for the specific uses for which they have been proven safe and 
effective, simultaneously allowing physicians to determine if they want to use those products 
for other medical purposes. Id. 
 16 Id. 
 17 Id. 
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two weeks, and are instructed to avoid strenuous exercise for four to six weeks.18 
Beyond the general risks of undergoing any surgery involving intravenous 
anesthesia, many other complications can arise from breast implant procedures, 
specifically. Most commonly, patients may experience capsular contracture, a 
tightening or hardening of the scar tissue surrounding the implant, causing the breast 
to feel hard and painful.19 Also common are implant ruptures, leaking, postoperative 
bleeding, loss of nipple sensation, scarring, and infection.20 
Furthermore, the medical risks of breast implants steadily increase in the years 
following the implant surgery. Breast implants last approximately ten years within 
the body, and the likelihood of a capsular contracture or related complication 
requiring surgery occurring increases over time.21 Thus, an adolescent who receives 
breast implants may require repeated surgeries, with all of the previously mentioned 
associated risks, throughout her lifetime.22 Additionally, breast implant surgery has 
been shown to increase the likelihood of insufficient lactation for breastfeeding.23 
Breast implants also interfere with preventative or diagnostic mammography, as 
mammography procedures increase the likelihood of implant leakage and rupture, 
and breast implants may lead to a failure to detect approximately fifty-five percent of 
cancerous breast tumors.24 Overall, the FDA has estimated that forty percent of 
patients who undergo breast implant surgery experience at least one serious 
complication within three years.25 
B. Prevalence of Breast Implant Surgery in the United States  
According to statistics compiled by the American Society of Plastic Surgeons 
(ASPS), 1.6 million cosmetic surgical procedures were conducted in the United 
States in 2011.26 Breast implant surgery has held the title of most common cosmetic 
surgical procedure since 2006.27 A total of 307,000 breast implant surgeries were 
performed in 2011, an increase of 4% from 2010.28 The national average surgeon or 
physician fee for a breast implant surgery is $3,388; as such, U.S. expenditures on 
breast implant surgery totaled $1,040,725,840 in 2011.29 
                                                          
 18 Id. 
 19 Id. 
 20 Id. 
 21 Id. 
 22 Id. 
 23 Id. 
 24 Id. 
 25 Stossel, supra note 3.  
 26 ASPS 2011 Statistics Report, supra note 6, at 5. 
 27 Id. 
 28 Id. at 8. 
 29 Id. at 20. 




C. Prevalence of Breast Implant Surgery Amongst Minors in the United States  
Although data for minors is not precisely segmented, ASPS found that people 
age thirteen to nineteen had the least number of cosmetic procedures in 2011, 
constituting two percent of total surgeries.30 Specifically, 8,892 breast implant 
surgeries were performed on patients aged thirteen to nineteen in 2011, which 
constituted three percent of the total number of breast implant surgeries performed 
that year.31 Although patients aged thirteen to nineteen may represent a small 
proportion of the total number of patients undergoing breast implant surgeries in the 
United States, the number of these breast implant surgeries performed on women 
thirteen to nineteen increased four percent from 2010 to 2011.32 The American 
Society for Aesthetic Plastic Surgery (ASAPS) has also gathered statistics regarding 
the prevalence of breast implant surgery among minors. The ASAPS report states 
that 125,397 cosmetic surgeries were performed on patients under eighteen in 2010, 
representing 1.3% of the total number of cosmetic surgery patients.33 Furthermore, 
the report indicates that 4,153 breast implant procedures were performed on women 
under the age of eighteen in 2010, also constituting 1.3% of the total number of 
breast implant surgeries conducted in that year.34 A cosmetic bilateral breast implant 
was the most frequently requested surgery amongst minors aged eighteen and under, 
at forty-seven percent.35 
III.   REPRESENTATIVE SITUATIONS IN WHICH THE FEDERAL GOVERNMENT 
MAINTAINS AGE-BASED REGULATIONS 
A. Tobacco Products 
Tobacco sales represent one major area in which the federal government has 
successfully mandated a nationwide minimum age, although this federal oversight is 
a fairly recent accomplishment. In Philip J. Hilts’ book on the history of the FDA, 
Protecting America’s Health, Hilts describes the years leading up to the FDA’s first 
statements asserting authority to regulate tobacco products. Hilts notes that “[t]he 
FDA had not actively pursued the subject before, not because Congress had 
prevented it, or because of anything in the law, but simply because it was a hornet’s 
nest. There was no nastier political tangle.”36 Despite the stacked political odds, the 
FDA proceeded to investigate the subject of tobacco, addiction, and public health 
throughout the early 1990s. Based on this research, the FDA determined that:  
the problem was not just that a drug was intentionally being delivered to 
smokers, but that the companies initially hooked smokers when they were 
                                                          
 30 Id. at 6. 
 31 Id. at 14. 
 32 Id. 
 33 AM. SOC’Y FOR AESTHETIC PLASTIC SURGERY, COSMETIC SURGERY NATIONAL DATA 
BANK 10 (2010), http://www.surgery.org/sites/default/files/Stats2010_1.pdf. 
 34 Id. 
 35 Id. at 12. 
 36 PHILIP J. HILTS, PROTECTING AMERICA’S HEALTH: THE FDA, BUSINESS, AND ONE 
HUNDRED YEARS OF REGULATION 292 (2003). 
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children. At bottom, smoking was a pediatric disease, even if the illness 
and death finally struck during adulthood. Thus, ultimately, the object of 
planned FDA regulation was not to ban smoking or to go after adult 
smokers, but simply to try to reduce the number of children who started.37 
In 1996, as a culmination of these years of study and analysis, the FDA 
promulgated a rule that regulated cigarettes and smokeless tobacco as medical 
devices and prohibited the sale of nicotine-containing cigarettes and smokeless 
tobacco to individuals under the age of eighteen.38 The access restrictions and 
advertising controls contained in these regulations were designed to reduce 
children’s and adolescents' easy access to cigarettes and smokeless tobacco and to 
significantly decrease the amount of positive imagery making these products so 
appealing to that age group.39 
The FDA’s cigarette regulations were challenged in Coyne Beahm, Inc. v. FDA.40 
Although the Supreme Court ultimately struck down the FDA’s rules in FDA v. 
Brown & Williamson Tobacco Corp.,41 holding that Congress had excluded tobacco 
products from the FDA’s jurisdiction, it was the subject-matter of the rules, rather 
than the manner of regulating their sale, that was primarily problematic. In Brown & 
Williamson, the Court clearly noted that under 21 U.S.C. § 360j(e) the FDA may 
restrict the sale, distribution, or use of a device it has jurisdiction to regulate “if, 
because of its potentiality for harmful effect or the collateral measures necessary to 
its use, [the FDA] determines that there cannot otherwise be reasonable assurance of 
its safety and effectiveness.”42  
After this first regulatory attempt failed, there was no nationwide minimum 
purchase age for tobacco products until March 2010, when the FDA issued a final 
rule prohibiting the sale of cigarettes or smokeless tobacco to people younger than 
eighteen.43 This rule was authorized by the Family Smoking Prevention and Tobacco 
Control Act of 2009 (the Act); the Act amended the Federal Food, Drug, and 
Cosmetic Act (FDCA) to provide the FDA with jurisdictional authority over tobacco 
products and required the FDA to issue new rules identical to those it originally 
                                                          
 37 Id. at 294. 
 38 Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco 
to Protect Children and Adolescents, 61 Fed. Reg. 44,396, 44,396 (Aug. 28, 1996) (to be 
codified at 21 C.F.R. pts. 801, 803, 804, 807, 820 and 897). The FDA determined that 
cigarettes and smokeless tobacco were combination products consisting of a drug (nicotine) 
and device components intended to deliver nicotine to the body, which FDA may regulate as a 
drug/device combination product using the Federal Food, Drug, and Cosmetic Act’s (FDCA) 
drug authorities, device authorities, or both. Id. at 44,400.  
 39 Id. at 44,396. 
 40 Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374, 1400 (M.D.N.C. 1997).  
 41 FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 156 (2000). 
 42 Id. at 129.  
 43 Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco 
to Protect Children and Adolescents, 75 Fed. Reg. 13,225, 13,225 (Mar. 19, 2010) (to be 
codified at 21 C.F.R. pt. 1140). 




promulgated in 1996.44 The Congressional findings supporting the Act focused on 
the adverse health effects tobacco products pose for children, the prevalence of 
tobacco advertising and marketing geared towards adolescents, and the need for 
comprehensive restrictions on the sale of tobacco products given the failure of past 
efforts focused solely on advertising and marketing restrictions.45 
B. Human Subjects Research on Minors 
Federal regulations also restrict the ability of minors to participate in biomedical 
research.46 Laws governing human subjects research in the United States grew out of 
various ethical guidelines and conventions developed by international organizations 
and tribunals beginning after World War II. The Nuremberg Code (the Code), 
developed in 1947 at the conclusion of the Nuremberg Military Tribunal trials, first 
addressed participation in biomedical research.47 Although the Code did not 
explicitly address guidelines for children as research subjects, the Code did 
emphasize the importance of voluntary, informed consent.48 As such, the guidelines 
specify that human subjects participating in research must “have the legal capacity to 
give consent; should be so situated as to be able to exercise free power of choice . . . 
and should have sufficient knowledge and comprehension of the elements of the 
subject matter involved as to enable him to make an understanding and enlightened 
decision.”49 Thus, while the Code did not impose explicit age restrictions for 
participation in biomedical research, following its principles of voluntary consent 
would generally prevent participation in biomedical research by minors. It appeared 
that children could not meet the Code’s standards for enlightened decision-making 
because they lacked the statutory or common law capacity to give consent to medical 
treatment and because they were viewed as unable to comprehend the subject matter 
of research and engage in an informed decision-making process.50  
The World Medical Association’s Helsinki Declarations were the first 
international guidelines to make specific recommendations for children’s 
participation in research.51 In 1975, “Helsinki II” explicitly categorized children as a 
                                                          
 44 Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, § 102, 123 
Stat. 1776, 1778–79 (2009) (codified as amended in scattered sections of 5 U.S.C., 15 U.S.C., 
and 21 U.S.C. (2006)). 
 45 See id.  
 46 See generally 45 C.F.R. § 46.101 (2009).  
 47 TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY TRIBUNALS UNDER 
CONTROL COUNCIL LAW NO. 10, 181–82 (U.S. Gov’t Printing Office, 1949) [hereinafter THE 
NUREMBERG CODE]; see also Leonard H. Glantz, Research with Children, 24 AM. J.L. & MED. 
213, 213 (1998). 
 48 THE NUREMBERG CODE, supra note 47, at 182. 
 49 Id.. 
 50 Leonard H. Glantz, The Law of Human Experimentation with Children, in CHILDREN AS 
RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW 105, 111–13 (Michael A. Grodin & Leonard 
H. Glantz eds., 1994). 
 51 Ann E. Ryan, Protecting the Rights of Pediatric Research Subjects in the International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals 
for Human Use, 23 FORDHAM INT’L L.J. 848, 869 (2000). 
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class of legally incompetent research subjects.52 In 1989, “Helsinki IV” urged that, in 
situations where a minor child was in fact able to give consent, the child’s consent 
should be required in addition to the consent of the minor’s parent or legal 
guardian.53 The International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use’s “Guidelines for 
Good Practice” suggested that human subjects who could not provide informed 
consent should not participate in non-therapeutic research unless certain conditions, 
such as low risks relative to benefits, were met.54  
Beyond these international ethical statements, the current U.S. regulatory 
framework governing children’s participation in human subjects research was also 
shaped by a series of disturbing incidents involving children as research subjects. 
One of the most infamous examples of this abusive treatment of underage research 
subjects occurred at the Willowbrook State School, a residential facility for mentally 
disabled children.55 From the 1950s through the 1970s, children living at 
Willowbrook were experimentally infected with hepatitis and observed over the 
natural course of the disease.56 
As the result of this history, federal laws governing human research subjects 
provide for enhanced protections when children are research participants.57 The 
mandate of 45 C.F.R. § 46 applies to human subjects research that is conducted or 
supported by any federal department or agency and to entities that receive federal 
funding for research, including universities.58 The regulation categorizes research 
into four categories according to degrees of risk and benefit.59 Research not 
involving greater than minimal risk is the most permissive category.60 “Minimal 
risk” means “that the probability and magnitude of harm or discomfort anticipated in 
the research are not greater in and of themselves than those ordinarily encountered in 
daily life or during the performance of routine physical or psychological 
examinations or tests.”61  
Research involving greater than minimal risk, but presenting the prospect of 
direct benefit to the individual subjects, may be funded if an Institutional Review 
Board (IRB) finds that:  
                                                          
 52 Id. at 870. 
 53 See id. at 872–73. 
 54 Id. at 920–21. 
 55 Susan Lederer & Michael Grodin, Historical Overview: Pediatric Experimentation, in 
CHILDREN AS RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW 15, 17 (Michael A. Grodin & 
Leonard H. Glantz eds., 1994). 
 56 Id. 
 57 See generally 45 C.F.R. § 46.101 (2009). 
 58 See id. 
 59 OFFICE FOR HUMAN RESEARCH PROTECTIONS, DEP’T OF HEALTH & HUMAN SERVICES, 
INSTITUTIONAL REVIEW BOARD GUIDEBOOK: CHAPTER VI SPECIAL CLASSES OF SUBJECTS 
(1993), available at http://www.hhs.gov/ohrp/archive/irb/irb_chapter6.htm (last updated 
1993). 
 60 Id. 
 61 45 C.F.R. § 46.102(i) (2009). 




(a) The risk is justified by the anticipated benefit to the subjects; (b) The 
relation of the anticipated benefit to the risk is at least as favorable to the 
subjects as that presented by available alternative approaches; and (c) 
Adequate provisions are made for soliciting the assent of the children and 
permission of their parents or guardians . . . .62  
Research involving greater than minimal risk and no prospect of direct benefit to 
individual subjects, but likely to yield generalizable knowledge about the subject’s 
disorder or condition, may be funded if an IRB finds that:  
(a) The risk represents a minor increase over minimal risk; (b) The 
intervention or procedure presents experiences to subjects that are 
reasonably commensurate with those inherent in their actual or expected 
medical, dental, psychological, social, or educational situations; (c) The 
intervention or procedure is likely to yield generalizable knowledge about 
the subjects' disorder or condition which is of vital importance for the 
understanding or amelioration of the subjects' disorder or condition; and 
(d) Adequate provisions are made for soliciting assent of the children and 
permission of their parents or guardians . . . .63 
The language of these regulations suggests that research on children that involves 
greater than minimal risk is generally inappropriate, even with parental consent to 
participation. At least one court has taken a firm stance on this issue. In Grimes v. 
Kennedy Krieger Inst., Inc.,64 the Court of Appeals of Maryland held that parents 
simply cannot consent to the participation of a child in non-therapeutic research in 
which there is any risk of injury or damage to the health of the subject.65 
On the other hand, it is the policy of the National Institutes of Health (NIH) that 
children should be “included in all human subjects research conducted or supported 
by the NIH unless there are scientific and ethical reasons not to include them.”66 This 
policy is driven by the need to develop scientific data regarding the risks and 
benefits of medical treatments for children. The best way to obtain this data is 
through clinical trials conducted on children, rather than relying solely on 
extrapolated data obtained from adult clinical trials.67 Thus, there is a fundamental 
tension between the scientific and societal goals for medical research that will 
benefit broad population segments and the rights of individual children participating 
in biomedical research. While excluding children from medical research could be 
                                                          
 62 45 C.F.R. § 46.405 (2009). 
 63 45 C.F.R. § 46.406 (2009). 
 64 Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807 (Md. 2001). 
 65 Id. at 858. 
 66 NIH Policy and Guidelines on the Inclusion of Children as Participants, in Research 
Involving Human Subjects, NAT’L INSTITUTES OF HEALTH (Mar. 6, 1998), http://grants1.nih. 
gov/grants/guide/notice-files/not98-024.html. 
 67 Id. 
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considered “an injustice to them as members of a community . . . their inclusion as 
individual participants in research may be an illegality to each of them.”68  
C. Female Genital Mutilation 
According to World Health Organization estimates, over 140 million women and 
girls have undergone female genital mutilation (FGM) worldwide, with the practice 
occurring primarily in Africa, Asia, and the Middle East, as well as in some 
immigrant communities in North America and Europe.69 Although FGM is 
performed for diverse and complex reasons, for many practitioners and in many 
cultures the surgeries are thought to add to the beauty of women and to ensure their 
marital prospects.70 Despite these cultural rationales, there is a powerful global 
movement resisting the practice of FGM. In the United States, the Federal 
Prohibition of Female Genital Mutilation Act outlaws FGM at the federal level.71 
Many states also have specific anti-FGM criminal statutes.72 The laws at the state 
level vary tremendously: some forbid FGM entirely, some ban the practice when 
performed on minors under eighteen, and some impose criminal liability on the 
parental act of consenting to the procedure.73  
The federal anti-FGM statute criminalizes the conduct of the individuals who 
perform FGM on minors, providing that “whoever knowingly circumcises, excises, 
or infibulates the whole or any part of the labia majora or labia minora or clitoris of 
another person who has not attained the age of 18 years shall be fined under this title 
or imprisoned not more than 5 years, or both.”74 The federal law also contains two 
defenses: first, where the operation is “necessary to the health of the person on 
whom it is performed, and is performed by a person licensed in the place of its 
performance as a medical practitioner” and second, when the operation is done for 
reasons of medical necessity “on a person in labor or who has just given birth.”75 
Finally, the statute states that, when applying the first medical necessity defense, “no 
account shall be taken of the effect on the person on whom the operation is to be 
performed of any belief on the part of that person, or any other person, that the 
operation is required as a matter of custom or ritual.”76 While the number of 
                                                          
 68 Bernard M. Dickens, The Legal Challenge of Health Research Involving Children, 6 
HEALTH L.J. 131, 132 (1998).  
 69 See Sara Corbett, A Cutting Tradition, N.Y. TIMES (Jan. 20, 2008), http://www.nytimes. 
com/2008/01/20/ magazine/20circumcision-t.html?_r=0. 
 70 See Richard A. Shweder, What About Female Genital Mutilation? And Why 
Understanding Culture Matters in the First Place, in ENGAGING CULTURAL DIFFERENCES: THE 
MULTICULTURAL CHALLENGE IN LIBERAL DEMOCRACIES 216, 224–25, 234–35, 242 (Richard 
A. Shweder et al. eds., 2002). 
 71 See 18 U.S.C. § 116(a) (2000). 
 72 See Holly Maguigan, Will Prosecutions for “Female Genital Mutilation” Stop the 
Practice in the U.S.?, 8 TEMP. POL. & CIV. RTS. L. REV. 391, 393 (1999). 
 73 See id. at 410. 
 74 See 18 U.S.C. § 116(a) (2000). 
 75 See 18 U.S.C. § 116(b)(1)–(b)(2) (2000). 
 76 See 18 U.S.C. § 116(c) (2000). 




prosecutions under this statute has been quite low,77 convictions can lead to a variety 
of collateral consequences for families involved, including deportation from the 
United States and the termination of parental rights.78 
IV.   SITUATIONS IN WHICH AGE-RELATED ACCESS CONTROLS ARE INAPPROPRIATE 
A. Over-the-Counter Diet Drugs 
The FDCA empowers the FDA with the statutory authority to regulate the safety, 
efficacy, and labeling of prescription and nonprescription drugs.79 Congress has 
codified the distinction between prescription and over-the-counter (OTC) drugs, 
explaining that a prescription drug is so designated “because of its toxicity or other 
potentiality for harmful effect, or the method of its use, or the collateral measures 
necessary to its use, is not safe for use except under the supervision of a practitioner 
licensed by law to administer such drug.”80 Accordingly, while prescription drugs 
must be dispensed by a pharmacist, OTC drugs can be sold in any retail 
establishment on open shelves.81 
Generally, OTC drug manufacturers are able to market their drugs without FDA 
preapproval by complying with a drug monograph designated by the FDA.82 As 
such, the FDA does not review each OTC drug product and label, but requires 
manufacturers to produce labels that follow specific format and content guidelines. 
For example, OTC drug labels must include information about ingredients, 
directions for proper use, and warnings against unsafe use and side effects.83 Beyond 
these basic requirements, the FDA can establish specific warnings for products that 
may cause harm under proper use,84 or require reasonable warnings to reduce 
foreseeable risks of harm posed by the product. For example, in 1998, the FDA 
observed that the availability in the marketplace of multiple container sizes of OTC 
laxative drugs containing sodium phosphates had caused consumer confusion, 
leading to accidental overdosing and consumer deaths.85 Given this potential for 
misuse, the FDA required an additional warning stating that “[t]aking more than the 
recommended dose in 24 hours can be harmful.”86 
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In 2007, the FDA approved Orlistat, the first OTC diet drug.87 Orlistat is 
designed to prevent the absorption of fat from food to achieve weight-loss; its effects 
are similar to laxatives.88 The FDA approved prescription strength Orlistat for weight 
management at a dosage of 120 milligrams nearly a decade earlier.89 The OTC 
version of Orlistat, marketed under the name Alli, is indicated for weight loss in 
overweight adults aged eighteen years and older in a dosage of sixty milligrams, half 
that of prescription strength.90 Although Alli’s labeling indicates that it is approved 
only for overweight adults, the FDA does not enforce this requirement, and Alli can 
be freely purchased in retail establishments and online without age or weight 
verification.91 
Because OTC weight management drugs like Alli are available without any real 
retail access controls, minors under eighteen are free to purchase these drugs and 
ignore age restrictions outlined in the product labeling. Indeed, abuse of diet pills by 
adolescents is a well-documented national public health problem.92 Data indicates 
that, in 2011, six percent of adolescent girls and four percent of adolescent boys 
reported past-month use of diet products without physician advice.93 Although diet 
drugs such as Alli are widely available on store shelves and advertised directly to 
consumers, abuse of OTC weight management products can cause serious health 
problems such as fluid and electrolyte disorders, cardiac arrhythmia, stroke, and 
hepatic and renal failure.94 
While OTC diet drugs like Alli are currently accessible to minors, despite labeled 
contraindications, commentators have called for increased regulatory controls to 
limit access and abuse of these drugs by youths. Such suggestions include 
designating Alli as behind-the-counter (BTC) pharmacy-only status, which would 
enable age verification by pharmacists.95 Despite these calls for increased regulation 
and tighter access controls for minors, the fact remains that teenagers are generally 
able to obtain easy access to OTC diet drugs. This is likely so because the FDA has 
explicitly considered the safety profile of diet drugs such as Alli, deemed them to be 
generally safe without the supervision of a physician, and therefore considers the 
benefits of widespread availability to outweigh the potential for misuse in the 
marketplace. 
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B. Indoor Tanning Beds 
The use of tanning beds by minors has come under increased scrutiny in recent 
years. Studies indicate that exposure to tanning beds when young is particularly 
harmful; for example, exposure to indoor tanning appliances can lead to an 
especially high increased risk for skin cancer when the age of first exposure is below 
twenty years of age.96 Moreover, statistics indicate that the use of tanning beds by 
minors is quite prevalent; an FDA advisory committee panel found in 2010 that forty 
to sixty percent of teenage girls surveyed had used tanning beds in the prior year, 
despite being aware of the associated risks of skin cancer.97 To respond to this 
growing problem, many states have enacted legislation that regulates the use of 
tanning facilities by minors. Eleven states ban the use of tanning beds for minors 
under a specified age, typically fourteen years; twenty-one states have opted instead 
to require only parental consent for minors under eighteen.98 Only California and 
Vermont ban all minors under eighteen from using tanning beds,99 while New Jersey 
has a similar ban for minors under the age of seventeen.100 The federal government, 
however, has not imposed a national age restriction for tanning beds. 
Although the FDA has not imposed a nationwide minimum age requirement for 
indoor tanning, the FDA has authority under 21 U.S.C. § 360j(e) to require that a 
device be restricted to use “upon such other conditions as the Secretary may 
prescribe in such regulation, if, because of its potentiality for harmful effect or the 
collateral measures necessary to its use, the Secretary determines that there cannot 
otherwise be reasonable assurance of its safety and effectiveness.”101 
This “upon such other conditions” language would allow the FDA to restrict the 
use of tanning beds to persons over the age of eighteen as long as the restriction is 
essential to the safe and effective use of tanning beds.102 Critics of proposed national 
age restrictions on tanning bed use argue that the government should not have more 
of a say in a teenager’s life than his or her own parents; they also suggest that 
minimum age requirements will “drive teens to riskier alternatives like home units 
and beaches.”103 On the other hand, advocates of these rules stress the limitations of 
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parental consent laws, noting that parental consent is often insufficient to protect 
minors because parents, like their teenage children, do not understand or do not take 
sufficient account of the risks of indoor tanning.104 Overall, although indoor tanning 
can be highly dangerous to the health of minors, tanning beds are widely viewed as 
an everyday consumer product. As such, it appears that public sentiment favors 
leaving their use and popularity to the regulation of the marketplace. 
C. Caffeine in Food, Beverages, and Dietary Supplements 
Caffeine is a pervasive ingredient in foods, beverages, and medicines sold in the 
United States. While most adult users can regularly ingest caffeine with few short-
term or long-term health effects, caffeine use can contribute to mental and physical 
health conditions amongst minors, and early caffeine addiction can lead to 
experimentation with more serious, illicit drugs.105 Nevertheless, caffeinated 
products are relatively unregulated. Federal regulatory requirements for caffeine 
vary greatly depending on whether the caffeinated product is classified as a food, 
drug, or dietary supplement.  
The FDA defines “food” as any article, or component of such article, “used for 
food or drink.”106 When caffeine is added as an ingredient to existing products, such 
as soda, or when foods and beverages such as coffee and chocolate contain caffeine 
naturally, caffeine as an additive is classified as a food.107 The FDCA states that 
caffeine is “generally recognized as safe when used in cola-type beverages in 
accordance with good manufacturing practice.”108 For beverages, the acceptable 
amount of caffeine allowable is 0.02% of the total content.109 Although caffeine does 
not have to be listed as an ingredient when it is a natural component of the food, 
solids or beverages to which caffeine is artificially added must list caffeine as an 
ingredient on product labeling.110 Manufacturers can evade even these fairly limited 
regulatory requirements by marketing their caffeinated products as dietary 
supplements, rather than food.111 Dietary supplements are regulated by the Dietary 
Supplement Health and Education Act of 1994 (DHSEA).112 High-caffeine energy 
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drinks are commonly sold as dietary supplements in order to avoid the FDA’s 
limitations on caffeine content in soft drinks and food labeling requirements.113  
Finally, the FDA defines drugs as any article “intended for use in the diagnosis, 
cure, mitigation, treatment, or prevention of disease.”114 Drugs that contain caffeine 
are subject to stricter regulatory controls than caffeinated products classified as food 
or dietary supplements.115 For example, the FDA limits the permissible caffeine 
content in OTC pain medicines to no more than sixty-five milligrams per dose116 and 
requires OTC drugs containing caffeine to include warning labels.117 Given the 
FDA’s varied approaches towards food, dietary supplements, and drugs, it is 
possible for the manufacturers of caffeinated products to avoid governmental 
controls by carefully crafting their marketing and advertising strategies. What is 
more profound is that, regardless of whether a caffeinated product is categorized as a 
food, drug, or dietary supplement, these products “may be purchased by adults, 
adolescents, and children at nearly every grocery, convenience store, or pharmacy in 
the United States. There are no national limitations on the sale or consumption of 
most . . . caffeinated products to children.”118 Thus, while minors lack the capacity to 
make fully informed decisions about consuming caffeinated products, and are more 
negatively impacted by excessive caffeine use than adults, minors are able to 
purchase most caffeinated products to the same extent as adults.119 
While limiting the sale of heavily-caffeinated products to children (in particular 
to children under the age of twelve, who the FDA has advised should avoid excess 
caffeine consumption) could be a feasible regulatory tactic, access restrictions on 
food products are generally highly unpopular.120 New York City Mayor Michael 
Bloomberg, dubbed “chief of the national food police,” has received backlash for his 
regulatory proposals related to soda.121 Often, food regulations that single out a 
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particular product or ingredient as unsafe or unhealthy are viewed as arbitrary and 
unproductive.122 Moreover, the fact that caffeine is found in countless varieties of the 
foods and beverages we consume makes access controls as a regulatory technique 
highly burdensome for both retailers and consumers.  
V.   A NATIONAL MINIMUM AGE REQUIREMENT FOR BREAST IMPLANTS SERVES THE 
SAME POLICY GOALS THAT OTHER AGE-RELATED ACCESS CONTROLS ARE 
DESIGNED TO FURTHER  
A.   Similarities to Federal Age Restrictions on Tobacco Products 
As discussed above, the quest to impose a national minimum age for the 
purchase of tobacco products was motivated by two primary concerns. First, the age 
restrictions were deemed appropriate because a key public health issue related to 
smoking was an expressly pediatric concern: reducing the risk that minors would 
begin smoking at a young age and subsequently become lifelong smokers. Second, 
federal legislation and regulation imposing age controls for tobacco products were 
driven by concerns that children were both especially vulnerable to, and the express 
targets of, destructive industry marketing.123 Concerns about minors undergoing 
breast implant surgery share similar themes. Breast implant surgery poses unique 
health and safety risks when the patient is an adolescent.124 Moreover, evidence 
suggests that teenagers are highly vulnerable to images in the media depicting 
cosmetically enhanced models and feel enormous pressure to “meet a culturally 
defined ideal of beauty.”125 Like age controls for tobacco, therefore, banning access 
to breast implant surgery for minors under eighteen would be designed to protect 
minors from a uniquely pediatric health concern. Age restrictions in both scenarios 
would provide enhanced protection when minors are targeted by pervasive media or 
advertising images and would prevent serious and scientifically proven health 
consequences from occurring in youths. 
B.  Similarities to Federal Age Restrictions in the Context of Human Subjects 
Research Involving Children  
The regulatory framework governing the participation of children in biomedical 
research highlights a rationale for federal intervention on the behalf of minors that is 
particularly relevant in the context of breast implant surgeries for patients under the 
age of eighteen. As discussed above, the regulations that control human subject 
research embody a keen skepticism towards parents who give permission to enroll 
their children in research trials that would expose the minor to risks without the 
promise of an individualized benefit in return.126 In this way, these regulations seem 
to indicate that federal intrusion into the parent-child relationship can be tolerated 
where parents intend to expose their children to unnecessary physical risks. This 
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governing principle is highly applicable in the context of parents who provide 
consent for their minor children to undergo medically unnecessary breast implant 
surgery. Thus, in both situations, parental consent that would subject a child to 
physical risk without the promise of individualized physical benefit for that child 
should be closely scrutinized.  
C.   Similarities to Federal Age Restrictions on the Practice of FGM 
Like FGM, breast implant surgery invades the bodily integrity of children to 
achieve permanent change in their sexual organs, involves a major surgical 
procedure, and carries the risk of serious side effects. FGM and breast implant 
surgery are also similar because the parents who consent to both procedures may 
share similar motivations. According to Professor Elaine M. Chiu, parents who 
consent to breast implant surgery want “to enhance the social acceptability of their 
children . . . [and] attain beauty, as measured by the dominant culture.”127 Chiu also 
notes that both procedures are integral to identity; in the case of breast implants, 
many girls and their parents turn to breast implant surgery as a means for the child to 
attain self-esteem and confidence.128 Despite these numerous similarities, however, 
practitioners who perform FGM surgery on minors are subject to criminal 
prosecution, while it is entirely legal for physicians to perform breast implant 
surgery on individuals under the age of eighteen as an off-label use.129 A lesson that 
could be gleaned from the example of FGM is that the federal government disfavors 
serious surgical procedures that invade the bodily integrity of minors when done 
primarily for cultural purposes, rather than based on medical need. Parental consent 
on behalf of a minor for both FGM and breast implant surgery is a decision “that 
subordinate[s] the child’s interests for the sake of the parent” and for the sake of 
conforming to societal norms.130 As such, the two procedures should be treated in a 
legally similar manner. 
D. Differences from Permissive Access to OTC Diet Drugs  
OTC drugs that can have harmful effects on minors are freely available to 
consumers of all ages in retail establishments, but this permissive access scheme is 
designed to further broader policy goals. The principle underlying the regulatory 
balance between OTC and prescription medicines is that, when OTC drugs are 
generally recognized as safe, allowing access to them on a fairly unrestricted basis 
furthers the interests of protecting the public’s health and relieving pharmacists and 
the public from burdensome restrictions on dispensing drugs.131 Thus, for OTC 
drugs, the FDA has explicitly considered the safety profile of the drug for all 
population segments that could access it in the marketplace and has decided that the 
                                                          
 127 Chiu, supra note 78, at 1811. 
 128 Id. 
 129 Zuckerman & Abraham, supra note 2, at 319.  
 130 Alicia Ouellette, Shaping Parental Authority over Children’s Bodies, 85 IND. L.J. 955, 
984 (2010). [hereinafter Ouellette, Shaping Bodies]. 
 131 Drug Approvals: Circumstances Under Which an Active Ingredient May Be 
Simultaneously Marketed in Both a Prescription Drug Product and an Over-the-Counter Drug 
Product, 70 Fed. Reg. 52,050, 52,051 (Sept. 1, 2005) (to be codified at 21 C.F.R. pt. 310). 
204 JOURNAL OF LAW AND HEALTH [Vol. 27:186 
 
 
benefits of widespread access outweigh the need for restrictions on dispensing it. On 
the other hand, breast implants are highly-regulated medical devices. When the FDA 
approved saline-filled breast implants for women over eighteen and silicone gel-
filled implants for women over twenty-two, they determined that there was 
insufficient evidence to show that breast implants are safe and effective for minors. 
The FDA made no explicit determination whatsoever that minors should be able to 
access breast implants in its approval process. Thus, off-label breast implant 
surgeries performed on minors only occur when physicians, who have been given 
broad flexibility by the FDA in the realm of off-label use, determine, on a case-by-
case basis, that these procedures are scientifically supported and in the best interests 
of a patient. Like the flexibility built into the OTC versus prescription drug 
dichotomy, the flexibility built into the off-label paradigm is designed to protect the 
public’s health and make sure people have access to treatments that will be 
medically beneficial to them. With off-label access to breast implants, however, this 
flexibility is unwarranted. The health of a minor may be compromised by 
undergoing breast implant surgery at a young age, and the minor patient is not 
physically harmed if she is unable to access the procedure until after she reaches the 
age of majority.  
E. Differences from Permissive Access to Consumer Products Such as Tanning 
Beds and Caffeine 
The objections to a national minimum age for tanning bed use highlight a key 
theme that frequently runs through the discourse associated with age-related product 
access controls: critics often argue that parental oversight should be the primary 
control on youth behavior.132 Although it is hardly compelling to suggest that parents 
should be free to authorize their children to use indoor tanning beds when there is 
scientific and medical consensus that tanning beds are “as carcinogenic as 
plutonium, arsenic, mustard gas, or cigarettes,”133 reasoning along these lines is 
potentially more persuasive in the context of tanning beds than it would be in the 
context of breast implants for minors. Like breast implants, tanning beds are 
regulated by the FDA as medical devices.134 Tanning beds are Class I medical 
devices. Class I devices are subject to minimal oversight; tanning beds are in the 
same category of medical devices as elastic bandages and examination gowns.135 
Breast implants, on the other hand, are Class III medical devices, the most 
stringently regulated category of medical devices.136 Tanning beds, therefore, are 
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more like ordinary consumer products than breast implants. Given that parents have 
a broad liberty interest in overseeing the everyday rearing of their children,137 it 
makes more sense to secure the primacy of parental control and authority in the 
context of tanning than it does when a child has a rare confrontation with choices 
regarding cosmetic breast implant surgery.  
The parental choice rationale is even stronger when it comes to caffeine, which is 
a pervasive consumer good, and a fixture in everyday life. The example of caffeine 
also highlights some additional differences between regulation of the stimulant and 
breast implants. While the scientific evidence suggests that caffeine is not seriously 
dangerous for children in its common usages,138 breast implant surgery carries 
significant health risks for minors. Moreover, practically speaking, strict age-based 
access controls for breast implants would be less onerous than similar restrictions on 
caffeine. The political backlash that would likely erupt if minors were banned from 
accessing caffeine makes it hard to imagine that age-based access controls for the 
stimulant would be effective or successful. Age-based access controls targeting 
physicians and designed to safeguard minors from unnecessary and proven safety 
risks would be a different scenario altogether.  
VI.   PROTECTING MINORS FROM ACCESSING BREAST IMPLANT SURGERY WARRANTS 
IMPINGEMENTS ON PHYSICIAN AND PARENTAL AUTONOMY  
A. Deference to Physicians Is Inappropriate in the Context of Breast Implants 
for Minors  
The Food and Drug Administration Modernization Act of 1997 affirms the 
longstanding principle of the FDA regulatory regime that the Agency must not “limit 
or interfere with the authority of a health care practitioner to prescribe or administer 
any legally marketed device to a patient for any condition or disease within a 
legitimate health care practitioner-patient relationship.”139 In certain circumstances, 
such as when a very ill patient could benefit from a newly-discovered indication of 
an approved drug, or when the patient is a member of a population group that is 
infrequently included in clinical trials that amass safety and effectiveness data, “off-
label use by prescribers is often appropriate and may represent the standard of 
care.”140 Given the need for flexibility and the desire to promote innovation when it 
is in the best interests of patients, the FDA merely constrains off-label use by 
physicians thusly: physicians using “a product for an indication not in the approved 
labeling . . . have the responsibility to be well informed about the product, to base its 
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use on firm scientific rationale and on sound medical evidence, and to maintain 
records of the product's use and effects.”141  
While there are indeed many good reasons to provide the medical profession 
with a significant degree of deference when it comes to off-label uses, it is not true 
“that physicians need to be unfettered in their prescribing practices to achieve 
maximal patient welfare.”142 In fact, off-label uses “for which there is little to no 
good evidence of safety or efficacy is antithetical to patient welfare and represents 
anachronistic medical ethics.”143 This section sets forth the reasons why breast 
implant surgery for minors falls into this latter category of off-label use, justifying 
regulatory intrusion into the doctor-patient relationship in order to better protect the 
best interests of minor patients.  
1. There Is No Evidence Breast Implant Surgery Is Safe for Minors 
Although a policy of non-interference with the physician-patient relationship is 
warranted in situations in which intrusions would impede sound medical judgment 
and stifle innovation, this rationale fails where the proposed off-label use is not 
supported by sound medical evidence of safety. Currently, there is no scientific 
evidence supporting off-label use of breast implants for minors. As discussed earlier, 
the FDA has approved saline-filled breast implants for women ages eighteen and 
older and silicone gel-filled implants for women ages twenty-two and older.144 One 
reason that these medical device approvals carry age specifications relates to the fact 
that, for both saline-filled and silicone gel-filled breast implants, the core clinical 
studies used by manufacturers to obtain FDA approval did not involve younger 
research subjects.145 For example, the information in Allergan’s Premarket Approval 
(PMA) application for its saline-filled implant indicates that the studies were 
conducted on women over the age of eighteen.146 In the PMA for Allergan’s silicone-
filled implant product the minimum age of patients is not specified, but the mean age 
of the subjects in the core study was thirty-four.147 Because PMA submissions “must 
provide valid scientific evidence collected from human clinical trials showing the 
device is safe and effective for its intended use,” the FDA could not approve the 
devices for an unstudied population group.148  
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Of course, this lack of clinical trial evidence is not dispositive, as almost all off-
label uses will, by definition, lack evidentiary support in PMA submissions and 
approval studies. What sets breast implant surgery for minors apart is that, on top of 
the lack of clinical trial data suggesting the safety and efficacy of these surgeries 
conducted on minors, there is affirmative evidence that minors are more vulnerable 
physically and mentally to adverse effects related to breast implants. First, in 
addition to the serious side effects associated with all breast implant surgeries, 
regardless of the age of the patient, there are specific risks associated with 
performing breast implant surgery on adolescents whose bodies are still developing. 
The bodies of teenaged girls continue to mature into adulthood; growth charts 
indicate that most girls gain weight between the ages of eighteen and twenty-one, 
which may affect a girl’s desire or need for breast implant surgery.149 In addition, 
because breast implants only last in the body for an average of ten years, minors who 
have breast implant surgeries will necessarily have to undergo successive operations 
across their lifetimes.150 In addition to the health risks posed by these additional 
surgeries, there will also be significant financial burdens for minors who, at a young 
age, sign on to carry the burden of breast implant maintenance with them for a 
lifetime. One plastic surgeon interviewed for an article in the New York Times 
described her fee structure: “she charges about $7,000 for breast augmentation; 
roughly $5,000 to remove implants; roughly $7,500 to replace old implants; and 
roughly $9,000 for surgery in which she removes implants and performs a breast lift 
using the patient’s own tissue.”151  
There is also reason to believe that, psychologically and mentally, minors are 
particularly inappropriate candidates for breast implant surgeries. As a general 
matter, research indicates that individuals who are drawn to cosmetic surgery in the 
first place are particularly vulnerable to reckless behavior. As many as fifteen 
percent of “patients seeking cosmetic treatments suffer from body dysmorphic 
disorder, a severe mental disorder that affects body perception and often leads 
sufferers to seek multiple unnecessary surgeries.”152 Further, women who have 
received breast implants are twice as likely as women of the same age who did not 
undergo surgery to commit suicide or die from substance abuse.153 Moreover, unlike 
other medical decisions, cosmetic surgery decisions are highly susceptible to peer 
influence.154 Adolescents are especially vulnerable to images in the media depicting 
cosmetically enhanced models and feel enormous pressure to “meet a culturally 
defined ideal of beauty.”155 It is precisely this pressure that motivates teen girls to 
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seek out cosmetic surgery, and studies indicate that peer influence is one of the most 
significant motivating factors for minors who wish to undergo cosmetic surgery.156  
Finally, even though minors only consent to breast implant surgeries through the 
substituted judgment of their parents, it is nevertheless troubling that minors lack 
fully-formed decision-making capacity when making the request for cosmetic 
procedures and putting themselves in this sort of situation. Studies show that teen 
brains are not fully developed to make critical decisions.157 For example, MRIs 
conducted on adolescents and adults indicate that adolescents “rely more on the 
amygdala, the area of the brain associated with the primitive impulses of aggression, 
anger, and fear. Adults, on the other hand, tend to rely on the frontal lobes, a cerebral 
area associated with impulse control and good judgment.”158 In a similar vein, other 
research shows that the regions of the brain associated with risk assessment and 
impulse control do not fully develop until late adolescence or later.159 Furthermore, 
studies show that adolescents are incapable of making cost-benefit analyses, score 
lower on measures of personal responsibility, and are less capable of viewing 
situations with a long-term perspective.160 Because of this, minors take risks to a 
greater degree than do adults, undervalue the consequences of their actions, and tend 
to make poor judgments.161  
2. Cosmetic Breast Implant Surgery Is, by Definition, Not Medically 
Necessary 
Given the evidence that minors are generally inappropriate candidates for breast 
implant surgery, it cannot seriously be argued that there is a medical need urgent or 
important enough to counsel performing breast implant surgeries on minors in the 
face of these serious safety concerns. Indeed, breast implants for minors are wholly 
unnecessary. Breast implant surgery is quite unlike other medical interventions 
because it involves taking unnecessary physical risks that are not offset by any 
physical benefits.162 Although it is possible that psychological or other intangible 
benefits may accrue to the cosmetic surgery patient, these theoretical benefits pale in 
comparison to the substantial risks of the medical procedure.163 In addition, the role 
of the medical provider in the cosmetic surgery context is quite different, as 
compared to other medical interventions.164 In general medical practice, physicians 
act according to professional guidelines, which restrict the use of invasive 
procedures to only “those that are medically effective as measured by objective 
scientific criteria.”165 This guideline alone can serve as a “safeguard against 
                                                          
 156 Id. 
 157 Diaz, supra note 9, at 251. 
 158 Id. 
 159 Id. 
 160 Id. 
 161 Id. at 251–52. 
 162 Ouellette, Body Modification, supra note 125, at 148. 
 163 Id. 
 164 Id. at 150. 
 165 Id. 




impulsive and reckless decision making.”166 Cosmetic surgery, on the other hand, is 
not focused primarily on medical efficacy because its goals are to achieve “aesthetic 
and social improvement.”167 While plastic surgeons are expected to perform only 
those surgeries that would benefit a patient, determining the degree to which a 
cosmetic procedure will benefit a patient is entirely subjective. Further, no study has 
shown that there is any long-term benefit of performing cosmetic surgery on 
minors.168 While some plastic surgeons are certainly capable of exercising good 
subjective judgments in this terrain, “there is simply no guarantee that a professional 
adult decision maker committed to preserving the health of the adolescent can be 
counted on to counter impulsive risk taking by adolescents for body modification.”169  
3. The Medical Profession May Be Amenable to Enhanced Regulation of 
Breast Implants for Minors  
There are indications from within the medical profession itself that restrictions on 
the ability of physicians to perform breast implant surgery on minors may be 
acceptable. First, in 2004, the ASPS adopted an official stance against breast implant 
surgery for patents under age eighteen.170 While this is not an enforceable standard, it 
suggests that at least certain medical professionals consider breast implant surgery 
performed on minors to run counter to medical ethics. 
Statements made by physicians during the FDA panel hearings regarding breast 
implant approvals provide another indication that there is a degree of discomfort 
from within the medical profession when it comes to performing breast implant 
surgery on minors. During the General and Plastic Surgery Devices Panel hearing on 
saline breast implant approval, various stakeholders in attendance raised concerns 
about allowing young women access to breast implant surgery.171 Several physicians 
noted that obtaining meaningful informed consent from teenagers and their parents 
can often be difficult. According to one speaker, this difficulty is largely related to 
the fact that the kind of information being given to potential breast implant surgery 
patients is largely “probabilistic information,” and “probabilistic thinking is the most 
abstract kind of thinking and the last one to develop in [the] range of skills and 
capacity that we have.”172 Several physicians in attendance agreed with this 
sentiment based upon their personal interactions with younger patients. For example, 
Doctor Charles Bailey noted that, “with respect to interacting with the patients, it’s 
not uncommon to be sitting in front of a very young patient where you feel like 
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nothing that you’re saying is being heard.”173 Another speaker, Doctor Mark Jewell, 
agreed with this sentiment, stating 
as your children are in the early 20s and certainly in the teens . . . it’s 
immediate gratification now. Don’t bother me with the details. I find that 
a lot of the younger people are not—I don’t feel like they are really 
listening and so sometimes I will impose a second visit on them or have 
them, you know, spend more time reading over the material and come 
back and sort of show me that they have an understanding of it.174  
Given that younger patients can have trouble properly processing information 
about risks and consequences related to breast implant surgery, it seems unlikely that 
they will be active and capable participants in the informed consent process 
alongside their parents and physicians. Although Dr. Jewell explicitly stated that he 
“would not operate on a 17-year-old,”175 he noted that it is his practice to spend 
much more time discussing long-term problems associated with breast implant 
surgery with his “very young patients.”176 Specifically, Dr. Jewell tells these young 
patients that they will likely “have at least one or two deflations during the next 50 
years and maybe more than that.”177  
Other speakers throughout the hearing offered additional concerns: that there is a 
lack of scientific data delineating the long-term health effects for young girls who 
have received breast implant surgery, and that young patients may suffer from 
emotional scars if their implants rupture or the patient finds out many years later that 
she will not be able to breastfeed her baby.178 Finally, the speakers also hinted at 
issues related to the excessive influence of peer pressure on young girls seeking 
cosmetic surgery. Dr. Bailey noted that he sometimes saw young teens brought into 
the surgeon’s office by “a mother who is pushing an implant on a daughter because 
of her early life experiences, or a boyfriend or a husband.”179 While Dr. Bailey stated 
that it was “not uncommon for [him] to refuse two or three patients a month based 
on some of these concerns,” this is merely Dr. Bailey’s personal policy, and not one 
that any other surgeon would have any obligation or duty to uphold.180  
Overall, there are several reasons why self-regulation by medical professionals is 
insufficient to protect minors who wish to undergo breast implant surgery from 
harm. First, there is no evidence that breast implant surgery performed on minors is 
safe given both the limitations of scientific data and the unique vulnerabilities and 
risk profiles of minors. Second, cosmetic breast implant surgery is never medically 
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necessary, so there are no public health concerns related to encouraging minors to 
delay their surgeries until after the age of majority. Finally, there are indications that 
the medical profession itself would approve of federal oversight and regulation of 
breast implant surgery for minors. Combined, these factors all support the notion that 
breast implant surgery performed on minors is a situation in which the doctor-patient 
relationship should not be considered inviolable. 
B. Deference to Parents Is Inappropriate in the Context of Breast Implants for 
Minors 
Parents have a fundamental constitutional right to the care and custody of their 
minor children. The Supreme Court has characterized this right as a liberty interest 
protected under the Due Process Clause of the United States Constitution and has 
affirmed the rights of “parents and guardians to direct the upbringing and education 
of children under their control.”181 Accordingly, fit parents are granted the 
presumption that they will act in the best interests of their children. The rationale 
underlying this presumption is that parents have what children lack in “maturity, 
experience, and capacity for judgment when making difficult life decisions;” thus, 
“due to their natural bond, parents will act in the best interests of their children.”182 
A parent’s liberty interest in the upbringing of his or her child encompasses 
medical decision-making on behalf of the minor child, as minors are generally 
considered to lack the ability to make mature decisions about their physical well-
being. Informed consent in the medical decision-making context requires patients to 
understand a physician’s disclosure of relevant risks and to exercise competent 
judgment. Minors are considered legally incompetent of this sort of evaluation; 
instead, physicians obtain informed consent from “parents, who are presumptively 
deemed competent on behalf of the minor.”183 Consequently, in most cases, a 
physician cannot legally treat an adolescent without parental consent.184  
Although the consent of a parent is typically substituted for that of the minor 
patient, there are a few exceptions to this general rule, and parents are unable to 
dictate all of a child’s medical decisions. In certain circumstances, a state may 
substitute its judgment that a medical procedure is in a child’s best interests, even if 
parents do not consent. These situations are ones in which “emergent needs take 
priority over parental rights and adolescent incompetence.”185 The first exception 
arises in the context of a medical emergency, defined as “any condition that requires 
prompt treatment to alleviate pain or in which delay of treatment could increase the 
risk to the health of the patient or, ultimately, anything causing the child to be 
frightened or hurt.”186 A second form of exception exists in some jurisdictions that 
have created special rules for emancipated minors or “mature minors.” An 
emancipated minor attains legal adulthood before reaching the age of maturity and 
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has the legal authority to consent to medical treatment without parental consent.187 In 
addition, the common law “mature minor doctrine” holds that minors “of sufficient 
intelligence and maturity to understand and appreciate both the benefits and risks of 
the proposed medical or surgical treatment . . . may consent to the treatment without 
parental consent.”188 Generally, the mature minor doctrine applies only to minors 
aged fourteen and above, who are deemed socially and psychologically mature 
enough to make their own healthcare decisions.189 The third and final type of 
exception is made when minors seek out certain sensitive medical treatments, such 
as those for substance abuse, mental health, sexually transmitted diseases, and 
adolescent pregnancy.190 When it comes to these types of adult-like interventions, the 
minor’s personal constitutional right to bodily integrity figures prominently in the 
equation and must be balanced against the parental liberty interest in the family and 
childrearing.  
Several factors combine together to create the overall rationale underlying the 
rules detailed above. First, while adolescents are considered rights-bearing citizens, 
certain policy concerns at times require these rights to be circumvented. While it is 
true that “constitutional rights do not mature and come into being magically only 
when one attains the state-defined age of majority,” it is also true that the peculiar 
vulnerabilities of children, the inability of children to make informed and mature 
decisions, and the centrality of the parental role in childrearing must all be protected 
at the same time.191 Therefore, a state’s interest in protecting minors validly justifies 
requirements that minors obtain parental consent before undergoing a medical 
procedure or that criminalize conduct involving minors that would be 
unconstitutional if applied to adults.192 Another factor that leads courts and 
policymakers to restrict the ability of minors to make health care decisions is the 
idea that minors play an important role in an autonomous family unit, and it is the 
parents who have a constitutionally protected right of control over this domain.193 In 
order to respect familial autonomy, parents are given broad discretion and authority 
to raise children as they see fit and make decisions about the care of their children 
without interference from the government. It is only when the state’s interest in 
protecting children outweighs parental liberty that the state can step in and “[take] 
the choice out of the hands of the parents” in the health care context, such as by 
requiring mandatory vaccinations or prohibiting procedures such as FGM.194  
This legal framework suggests a presumption that parents, in consultation with 
doctors, are best situated to determine the best interests of the child. In the context of 
consenting to breast implant surgery on the behalf of a minor child, this presumption 
does not hold. Primarily, this is so because parental-physician decision-making in 
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this context can be marred by conflicts of interest. The philosopher Michael Sandel 
has written about the issue of parents seeking enhancements for their children; he 
notes that parenthood should involve an appreciation of “children as gifts as they 
come, not as objects of our design or products of our will or instruments of our 
ambition.”195 Sandel does not imply that parents should “shrink from shaping and 
directing the development of their child;” on the contrary, he believes that parents 
have an obligation to heal their children and prevent sickness and injury.196 The 
distinction as Sandel sees it, however, is that, while a parent who consents to casting 
a child’s broken leg does not reject the child as she came, a parent who consents to a 
medical intervention that is purely cosmetic fails to appreciate the child as a gift. The 
parent’s imposition of his or her will on the child distorts the parent-child 
relationship.197 Thus, when a parent consents to an extreme medical intervention, 
geared toward shaping the child toward social acceptability but promising no 
demonstrable medical benefit, questions of conflicts of interest on behalf of the 
caregiver cause the weight to shift against applying the usual parent-doctor decision-
making presumption to this decision.198 
In fact, it would not be unprecedented to override parental consent in this sort of 
scenario. There are two situations in which the legal system has explicitly removed 
parental consent from the equation when there are concerns about the motivations 
parents have for consenting to medical interventions or procedures on behalf of their 
children. First, most courts have held that parental consent is insufficient to authorize 
procedures in which a child would serve as an organ donor; in these situations, 
judicial approval is necessary.199 There are two reasons why courts typical displace 
parents as decision-makers in this context. First, parents frequently have conflicts of 
interest; the beneficiary of the proposed organ donation is often an ill family 
member, which makes it hard for parents to independently consider the best interests 
of the donor child.200 Second, courts have stated that “extra caution is needed when a 
parent wants to consent to a medical procedure that offers no medical benefit to the 
child.”201 In Little v. Little, for example, a Texas appellate court found that the 
mother of a fourteen-year-old girl could not authorize a transplant of her daughter’s 
kidney into her son; the court so held because parents can only authorize “medical 
treatment,” defined as “the steps taken to effect the cure of an injury or disease.”202 
Donation of a kidney was not considered medical treatment, even though it might 
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confer psychological benefits, because donation would not improve the physical 
health of the donor.203
 
Another area in which parental consent is considered inadequate to authorize a 
minor’s medical intervention is when parents seek to permit the sterilization of their 
children. As with organ donation, potential parental conflicts of interest have played 
an important role in the development of this legal framework. Sterilization is 
typically proposed for developmentally disabled and mentally ill minors or 
incompetent adult children. Parents that seek to obtain sterilization for their children 
may be worried that the burden of that child’s future unwanted pregnancy would fall 
on them; the desire to avoid this situation can mar the judgment of the parent and 
interfere with his or her ability to independently consider the child’s best interests.204  
Overall, although parents typically enjoy broad liberties when it comes to raising 
children and making important life decisions on their behalf, the risks to minors 
associated with breast implants are sufficient to warrant a degree of governmental 
interference in this relationship. This is especially so in the context of cosmetic 
surgery for minors. When parents consent to expose their children to real medical 
risks during purely cosmetic procedures, with only the promise of social or 
psychological benefits accruing to the child, their motivations may be marred by 
conflicts of interest. As such, enhanced scrutiny is necessary.
 
VII.   CONCLUSION 
This article has attempted to make sense of the policy rationales underlying the 
federal government’s imposition of age-based access controls on consumer products, 
medical procedures, and other interventions. This article argues that banning breast 
implants for minors under the age of eighteen would serve similar policy goals to 
age restrictions successfully employed elsewhere, such as for tobacco products, 
participation in biomedical research, and female genital mutilation. While critics of 
age-based access controls will be quick to attack this proposal as unduly burdening 
the autonomy of physicians and parents, this article has also demonstrated that there 
are reasons to believe that the traditional parental-physician consent framework will 
not protect the best interests of minors who seek breast implants. As such, this article 
ultimately calls for consistency. Minimum age restrictions for breast implants would 
cause no harm for minor patients, but could avoid serious and unnecessary harms. 
Thus, age restrictions should be applied in the context of breast implant surgery for 
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